Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy

References

• Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6(Suppl 1)S11–S14
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380–4
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Wirth K, Mertelsmann R, Lindemann A, Brennscheidt U. Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2. Eur J Cancer 1997; 33: 1050–4
   PubMedGoogle Scholar
• Konjevic G, Jovic V, Jurisic V, Radulovic S, Jelic S, Spuzic I. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. Clin Exp Metastasis 2003; 20: 647–55
   PubMed Web of Science ®Google Scholar
• Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2- based immunotherapy in humans. Cancer Res 1989; 49: 7086–92
   PubMed Web of Science ®Google Scholar
• Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L, von der Maase H. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study. Melanoma Res 2000; 10: 66–77
   PubMed Web of Science ®Google Scholar
• Schmidt H, Larsen S, Bastholt L, Fode K, Rytter C, von der Maase H. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Ann Oncol 2002; 13: 1919–24
   PubMed Web of Science ®Google Scholar
• Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, Bornfeld N. Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: A clinicopathological study. Oncology 2000; 58: 83–8
   PubMedGoogle Scholar
• Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988; 96: 379–94
   PubMed Web of Science ®Google Scholar
• Strausser JL, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J Immunol 1978; 121: 1491–5
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984; 160: 1147–69
   PubMed Web of Science ®Google Scholar
• Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T–cell growth factor. Cancer Res 1981; 41: 4420–5
   PubMed Web of Science ®Google Scholar
• Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002; 3: RESEARCH0035
   PubMedGoogle Scholar
• Donskov F, Bennedsgaard KM, von der MH, Marcussen N, Fisker R, Jensen JJ, et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 2002; 87: 194–201
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002; 196: 254–65
   PubMed Web of Science ®Google Scholar
• Baldus SE, Zirbes TK, Weidner IC, Flucke U, Dittmar E, Thiele J, et al. Comparative quantitative analysis of macrophage populations defined by CD68 and carbohydrate antigens in normal and pathologically altered human liver tissue. Anal Cell Pathol 1998; 16: 141–50
   PubMedGoogle Scholar
• Fukuda M. Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. J Biol Chem 1991; 266: 21327–30
   PubMed Web of Science ®Google Scholar
• Hernberg M, Turunen JP, Muhonen T, Pyrhonen S. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 1997; 20: 488–95
   PubMedGoogle Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71–8
   PubMed Web of Science ®Google Scholar
• Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625–9
   PubMed Web of Science ®Google Scholar
• Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 1999; 57: 138–42
   PubMed Web of Science ®Google Scholar
• Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000; 85: 182–8
   PubMed Web of Science ®Google Scholar
• Boudreau N, Myers C. Breast cancer-induced angiogenesis: Multiple mechanisms and the role of the microenvironment. Breast Cancer Res 2003; 5: 140–6
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577–83
   PubMed Web of Science ®Google Scholar